Frequent Klebsiella pneumoniae Urinary Tract Infections in a Patient Treated with Ruxolitinib

Ruxolitinib is a targeted agent that inhibits Janus 2 Kinase and is approved for use in Polycythemia Vera and Primary Myelofibrosis. Its mechanism of action involves inhibition of cellular proliferation via the Janus kinase/signal transducer and activator of transcription proteins pathway. Ruxolitin...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanna, Ramy M., Khalid, Maham, El-Nour, Lama Abd, Selamet, Umut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784127/
https://www.ncbi.nlm.nih.gov/pubmed/31527456
http://dx.doi.org/10.3390/antibiotics8030150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784127/
https://www.ncbi.nlm.nih.gov/pubmed/31527456
http://dx.doi.org/10.3390/antibiotics8030150

Ejemplares similares